The disclosure relates to high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, wherein the beta-iron hydroxide oxide content is less than 6% by weight based on the total weight thereof. The disclosure also relates to the method of producing the ferric citrate using sodium hydroxide and the use of the ferric citrate for treating amelioration of hyperphosphatemia. The method includes a step of forming an iron-containing precipitate comprising bringing ferric chloride into contact with sodium hydroxide in less than 2 hours at a liquid temperature of 0 °C to 10 °C, in an aqueous medium to form an iron-containing precipitate； a step of generating an aqueous solution of iron(III) citrate comprising bringing citric acid into contact with the iron-containing precipitate in an aqueous medium and generating an aqueous solution of iron(III) citrate via heating； and a step of precipitating iron(III) citrate comprising bringing the aqueous solution of iron(III) citrate into contact with an organic solvent to precipitate the iron(III) citrate.
